US · Healthcare · Biotechnology
EPS came in at -2.34 against a street estimate of -2.50 — a beat of 6.4%.
Analysts rate Inhibrx Biosciences, Inc. a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $266.67.
| Fund | Stake |
|---|---|
| Morgan Stanley - Brokerage Accounts | 8.89% |
| Perceptive Advisors LLC | 8.82% |
| Sanofi | 7.87% |
| Viking Global Investors LP | 7.64% |
| HighTower Advisors, LLC | 5.92% |
| Bank of America Corp | 5.72% |
| BlackRock Inc | 5.61% |
| Schonfeld Strategic Advisors LLC | 4.74% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • Inhibrx Biosciences, Inc. filed a Form 8-K dated September 28, 2026. • The filing reports that the company posted an updated corp | 2026-09-28 |
| Reg FD disclosure · Q3 2026 INHIBRX BIOSCIENCES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Primary endpoint met: INBRX-106 + pembrolizumab achieved 48.3% confirmed objective r | 2026-09-08 |
| Quarterly report · Q2 2026 INHIBRX BIOSCIENCES, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $133.3 million as of June 30, 2026 (up from $124.2 million | 2026-08-13 |
| Results announced · Q3 2026 INHIBRX BIOSCIENCES Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net loss Q2 2026: $36.7 million ($2.34 per share) vs. $28.7 million ($1.85 per shar | 2026-08-13 |
| Material agreement · Q3 2026 INHIBRX BIOSCIENCES, INC. – FORM 8-K SUMMARY Report Date: July 15, 2026 --- HEADLINE NUMBERS • Total Credit Facility Expanded to $500.0 million – i | 2026-07-16 |
| Reg FD disclosure · Q2 2026 INHIBRX BIOSCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • FDA accepted Biologics License Application (BLA) for ozekibart (INBRX-109) on June 1 | 2026-06-15 |
| Quarterly report · Q1 2026 INHIBRX BIOSCIENCES, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $161.7 million (March 31, 2026) vs. $124.2 million (D | 2026-05-14 |
| Proxy statement · Q4 2025 INHIBRX BIOSCIENCES, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 – Election of Two Class II Directors: Vote to | 2026-04-23 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Inhibrx Biosciences, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.